Overview / Abstract: |
Target Audience This activity is designed to meet the educational needs of physicians, physician assistants, nurses, pharmacists, and other healthcare professionals. Program Overview Direct oral anticoagulants (DOACs) are lifesaving drugs for many patients, with transformative impact for patients with atrial fibrillation (AF) and thromboembolism, but they are not without risks. Anticoagulant adverse events have presented hurdles for both healthcare providers and patients, with bleeding complications at the forefront. Although bleeding with anticoagulants is rare, it can result in serious complications necessitating effective reversal strategies. As the treatment landscape of anticoagulant reversal evolves with new approvals, it is essential that the critical care team managing patients on anticoagulation therapy have an in-depth understanding of anticoagulation reversal agents for treatment and management of bleeding. Participants of this activity will gain understanding of DOACs, the risk of bleeding with DOACs, the differences and similarities of available novel reversal agents, and most importantly, practical strategies for implementing these agents into the critical care setting. Learning Objectives Upon completion of this activity, participants should be better able to: Appraise the risk of bleeding with DOAC therapy, describe the risk factors associated with bleeding, and examine the strategies to mitigate these risks in order to improve patient and healthcare system outcomes. |
Expiration |
May 18, 2021 |
Discipline(s) |
Nursing CNE, Pharmacy CPE, Physician CME |
Format |
Online |
Credits / Hours |
1.5 AMA PRA Category 1 Credit(s)™ |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Faculty Gregory Piazza, MD John Fanikos, MBA, RPh Jorge Antonio Gutierrez, MD |
Sponsors / Supporters / Grant Providers |
Portola |
Keywords / Search Terms |
Relias LLC Relias LLC., FREE CME., Free CE CME |